Pneumology - Original Articles Open access

Drug resistance in patients with tuberculosis: a study from a tertiary care center in northern India

Authors

Published
23 September 2026
Issue
Early Access
Section
Pneumology - Original Articles
DOI
10.4081/monaldi.2026.3932

Abstract

Tuberculosis (TB) continues to be a major global health challenge, with India contributing a significant share of the burden. Drug-resistant TB (DR-TB) is additionally responsible for the huge numbers. Despite the magnitude of the problem, there is a relative paucity of data with respect to the different patterns of DR-TB from Northern India. A retrospective, observational study was undertaken at the Department of Pulmonary Medicine at Chest and TB Hospital, Government Medical College, Patiala, Punjab, India, to analyze the drug resistance profile of Mycobacterium tuberculosis and associated risk factors, essential for aiding clinicians and evaluating evidence to strengthen programmatic strategies, with an aim to ultimately reduce the overall burden of TB. A total of 14,142 microbiologically confirmed M. tuberculosis cases from 2022-2024 were reviewed. Resistance patterns were characterized according to national guidelines. The prevalence of resistance patterns and associations between drug resistance and demographic variables, treatment and contact history, and comorbidities (HIV co-infection, diabetes mellitus, alcohol, and smoking) were analyzed using chi-square tests and univariate and multivariate logistic regression. In this cohort, the median age of included patients was 37 years, with the majority from 21-40 years (41.01%) and predominantly male gender (60.72%). The overall prevalence of DR-TB was 8.6%. INH monoresistance accounted for 50.53% of DR-TB, with 35.99% harboring katG and 14.54% inhA gene mutations. katG mutations were significantly higher in newly diagnosed patients (37.7%, p=0.006), those with a positive contact history (37.6%, p=0.027), diabetics (43.6%, p=0.038), and individuals with tobacco exposure (49.1%, p=0.034). inhA mutations were strongly associated with HIV co-infection (32.30%, p=0.005). Rifampicin resistance was more frequent among previously treated cases (15.3%, p<0.001), patients with no contact history (13%, p=0.003), and those with HIV co-infection (19.40%, p=0.026). Multivariate analysis demonstrated that female gender [adjusted odds ratio (AOR) 1.15, p=0.030], previous treatment history (AOR 1.78, p<0.001), and absence of contact history (AOR 1.74, p<0.001) had higher odds of having DR-TB. These findings, when interpreted in the context of existing literature, suggest that factors contributing to the development of resistance are either acquired through treatment failure or community transmission. Individual host factors, including gender and the presence of comorbidities such as HIV, diabetes, and tobacco exposure, further increase the risk. Understanding the epidemiology of drug resistance is crucial to improve patient outcomes, curb the burden of TB in our region, and eventually advance the nation's TB elimination goals.

Keywords

Ethics Approval

The study was approved by the Institute’s Ethics Committee (vide letter No. Trg. 9(310)2024/28113 dated 13 September 2024).

References

  1. WHO. Global tuberculosis report 2024. 1st ed. Available from: https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2024
  2. Ministry of Health and Family Welfare. National guidelines for management of drug resistant TB. Available from:https://tbcindia.mohfw.gov.in/wp-content/uploads/2025/01/National-Guidelines-for-Management-of-DR-TB_Final.pdf
  3. Myneedu VP, Singhal R, Khayyam KU, et al. First and second line drug resistance among treatment naïve pulmonary tuberculosis patients in a district under Revised National Tuberculosis Control Programme (RNTCP) in New Delhi. J Epidemiol Glob Health 2015;5:365-73. DOI: https://doi.org/10.1016/j.jegh.2015.04.002
  4. Sinha P, Srivastava GN, Gupta A, Anupurba S. Association of risk factors and drug resistance pattern in tuberculosis patients in north India. J Glob Infect Dis 2017;9:139-45. DOI: https://doi.org/10.4103/jgid.jgid_167_16
  5. Chawla GK, Garg K, Kaur K, et al. Pattern of drug resistance among patients of pulmonary tuberculosis. Indian J Tuberc 2022;69:669-74. DOI: https://doi.org/10.1016/j.ijtb.2021.10.003
  6. Ministry of Health and Family Welfare. India TB Report 2024 Available from: https://tbcindia.mohfw.gov.in/wp-content/uploads/2024/10/TB-Report_for-Web_08_10-2024-1.pdf
  7. Ministry of Health and Family Welfare. National Tuberculosis Elimination Programme . Available from: https://dghs.mohfw.gov.in/national-tuberculosis-elimination-programme.php
  8. Sharma P, Visnegarwala F, Tripathi V. Burgeoning double burden of tuberculosis and diabetes in India: magnitude of the problem – strategies and solutions. Clin Epidemiol Glob Health 2014;2:107-16. DOI: https://doi.org/10.1016/j.cegh.2013.03.002
  9. Debnath A, Nath R, Mondal A, et al. Prevalence of tobacco consumption among pulmonary tuberculosis patients and its correlation with tuberculosis incidence: a systematic review and meta-analysis in the Indian context. Monaldi Arch Chest Dis Arch 2026;96:3324. DOI: https://doi.org/10.4081/monaldi.2025.3324
  10. Mondal T, Sarkar A, Chaudhuri SJ, Rahaman J. Tuberculosis and HIV coinfection and rifampicin-resistant tuberculosis among patients living with HIV in Northern part of West Bengal, India. Asian J Med Sci 2023;14:81-7. DOI: https://doi.org/10.3126/ajms.v14i1.47930
  11. Salindri AD, Sales RMF, DiMiceli L, et al. Isoniazid monoresistance and rate of culture conversion among patients in the state of georgia with confirmed tuberculosis, 2009-2014. Ann Am Thorac Soc 2018;15:331-40. DOI: https://doi.org/10.1513/AnnalsATS.201702-147OC
  12. Baluku JB, Mugabe P, Mulwana R, et al. High prevalence of rifampicin resistance associated with rural residence and very low bacillary load among TB/HIV-coinfected patients at the National Tuberculosis Treatment Center in Uganda. BioMed Res Int 2020;2020:2508283. DOI: https://doi.org/10.1155/2020/2508283
  13. Sharling L, Marks SM, Goodman M, et al. Rifampin-resistant tuberculosis in the United States, 1998-2014. Clin Infect Dis 2020;70:1596-605. DOI: https://doi.org/10.1093/cid/ciz491
  14. Rehman A ur, Khattak M, Mushtaq U, et al. The impact of diabetes mellitus on the emergence of multi-drug resistant tuberculosis and treatment failure in TB-diabetes comorbid patients: a systematic review and meta-analysis. Front Public Health 2023;11:1244450. DOI: https://doi.org/10.3389/fpubh.2023.1244450
  15. Hatiya M, Merid Y, Mola A, et al. Prevalence of drug-resistant Mycobacterium tuberculosis and its associated factors among tuberculosis patients attending Dilla university referral hospital, Ethiopia. BMC Infect Dis 2025;25:797. DOI: https://doi.org/10.1186/s12879-025-11191-z
  16. Singh N, Singh AK, Sarita S, et al. Prevalence and genetic analysis of isoniazid-resistant tuberculosis in eastern Uttar Pradesh, India. Cureus 2025;17:e80243. DOI: https://doi.org/10.7759/cureus.80243
  17. Alavi-Naini R, Sharifi-Mood B, Metanat M. Association between tuberculosis and smoking. Int J High Risk Behav Addict 2012;1:71-4. DOI: https://doi.org/10.5812/ijhrba.5215
  18. Zellweger JP. Tobacco and tuberculosis. Monaldi Arch Chest Dis 2008;69:403. DOI: https://doi.org/10.4081/monaldi.2008.403
  19. Prasanna MV, Muthuraj R, Raj RV, et al. Clinico-microbiological profile and treatment outcomes in patients with isoniazid monoresistant tuberculosis in South India. Eur Respir J 2023;62. DOI: https://doi.org/10.1101/2023.01.31.23285245
  20. Kendall EA, Fofana MO, Dowdy DW. The burden of transmitted multi-drug resistance among epidemics of tuberculosis: A transmission model. Lancet Respir Med 2015;3:963-72. DOI: https://doi.org/10.1016/S2213-2600(15)00458-0
  21. Garg K, Saini V, Dhillon R, Agarwal P. Isoniazid mono-resistant tuberculosis: time to take it seriously. Indian J Tuberc 2019;66:247-52. DOI: https://doi.org/10.1016/j.ijtb.2019.04.001
  22. Mishra GP, Mulani JD. First national anti-tuberculosis drug resistance survey (NDRS) from India - an eye opener. J Infect Epidemiol 2018;1:1117. DOI: https://doi.org/10.29245/2689-9981/2018/2.1117
  23. Goyal V, Kadam V, Narang P, Singh V. Prevalence of drug-resistant pulmonary tuberculosis in India: systematic review and meta-analysis. BMC Public Health 2017;17:817. DOI: https://doi.org/10.1186/s12889-017-4779-5

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2026 The Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.